Single dose dry powder inhaler for asthma and COPD treatments

  • Bona Pharma

Increasingly more people are suffering from respiratory issues such as asthma and COPD alongside the accelerating steps of the civilization process and serious air pollution. In order to bring a brighter and healthier future to asthma and COPD patients, BONA has made considerable investment in advanced R&D, resulting in the production of the company's cutting-edge single-dose dry powder inhaler (DPI).

BONA's single-dose DPI is compact and portable, featuring an ergonomic design with easy-breathe technology which makes the product simple to use. The materials are all EP, USP and CP compliant, and the product is produced in a Class 100,000 Clean Room according to GMP regulations.

Features of BONA’s single dose dry powder inhaler (DPI):

  • Applicable to capsule 3#
  • Ergonomic design, simple to use, easy-breathe technology
  • Compact and portable
  • Aerodynamic tests can be performed
  • Air resistance parameter is equivalent with the device of branded drug
  • Materials comply with EP, USP and CP
  • Clean Room: Class 100,000 (Class D) according to GMP regulations
  • Certificate: CE and US FDA approval
  • Customization: color, size and any new design can be customized

See also

BONA Pharma’s disinfection topical spray pump for 100ml PET Bottle

With the COVID-19 coronavirus epidemic spreading, the World Health Organization is telling people to stay at home, wash hands frequently, and disinfect continuously. In order to help people stay stafe, BONA has launched a multi-volume liquid PET bottle with topical spray pump ideal for disinfection. Although these are difficult times, BONA wants everyone to be strong, stay safe, and act accordingly now in order to reduce the spread of the virus.

  • Jo Webb
  • Product Info
  • English
  • Created 06 May 2021
  • Modified 06 May 2021
  • Hits 2804